Rain Therapeutics Inc.
NASDAQ:RAIN
1.21 (USD) • At close January 25, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 3.965 | 14.98 | 16.677 | 19.078 | 14.51 | 14.257 | 13.555 | 14.672 | 15.284 | 5.489 | 5.328 | 4.172 | 7.893 | 1.473 | 1.762 |
| General & Administrative Expenses
| 4.113 | 5.414 | 5.066 | 4.479 | 3.901 | 3.461 | 3.895 | 3.405 | 3.154 | 2.7 | 1.48 | 1.28 | 0.591 | 1.119 | 0.668 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 4.113 | 5.414 | 5.066 | 4.479 | 3.901 | 3.461 | 3.895 | 3.405 | 3.154 | 2.7 | 1.48 | 1.28 | 0.591 | 1.119 | 0.668 |
| Other Expenses
| 0 | 2.837 | 0 | 0 | 0 | 0 | 0 | 0 | 0.001 | 0 | 0 | 0 | -1.891 | -0.005 | -0.128 |
| Operating Expenses
| 8.078 | 20.394 | 21.743 | 23.557 | 18.411 | 17.718 | 17.45 | 18.077 | 18.438 | 8.189 | 6.808 | 5.452 | 8.484 | 2.592 | 2.43 |
| Operating Income
| -8.078 | -23.231 | -21.743 | -23.557 | -18.411 | -17.718 | -17.45 | -18.077 | -18.438 | -8.189 | -6.808 | -5.452 | -8.484 | -2.592 | -2.43 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 1.044 | -2.837 | 1.259 | 0.882 | 0.37 | 0.107 | 0.056 | 0.094 | 0.001 | 0.006 | 0.008 | 0.009 | -1.891 | -0.005 | -0.128 |
| Income Before Tax
| -7.034 | -22.064 | -20.484 | -22.675 | -18.041 | -17.611 | -17.394 | -17.983 | -18.426 | -8.183 | -6.8 | -5.443 | -10.446 | -2.624 | -2.569 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| -0.154 | 1.67 | -1.259 | 0.003 | -0.37 | -0.107 | -0.056 | 0.002 | 0.001 | 0.006 | 0.008 | 0.009 | -1.82 | 0.028 | -0.097 |
| Net Income
| -7.034 | -22.064 | -19.225 | -22.678 | -17.671 | -17.504 | -17.338 | -17.985 | -18.426 | -8.183 | -6.8 | -5.443 | -10.446 | -2.624 | -2.569 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -0.19 | -0.61 | -0.53 | -0.7 | -0.67 | -0.66 | -0.65 | -0.68 | -0.7 | -0.39 | -0.26 | -0.51 | -0.98 | -0.25 | -0.24 |
| EPS Diluted
| -0.19 | -0.61 | -0.53 | -0.7 | -0.67 | -0.66 | -0.65 | -0.68 | -0.7 | -0.39 | -0.26 | -0.51 | -0.98 | -0.25 | -0.24 |
| EBITDA
| -8.078 | -17.54 | -21.743 | -23.557 | -18.393 | -17.696 | -17.428 | -17.983 | -18.405 | -8.169 | -6.785 | -5.431 | -10.362 | -2.579 | -2.523 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |